Edesa Biotech, Inc (EDSA)

Etorro trading 970x250

About Edesa Biotech, Inc

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada. Address: 100 Spy Court, Markham, ON, Canada, L3R 5H6

Edesa Biotech, Inc News and around…

Latest news about Edesa Biotech, Inc (EDSA) common stock and company :

EDSA: Additional Favorable Mortality Reductions Identified in COVID-19 Trial…
21 Oct, 2021 Yahoo! Finance

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Additional Mortality Benefits Identified in Phase 2 COVID-19 Trial On October 19, 2021, Edesa Biotech, Inc. (NASDAQ:EDSA) announced additional results from the Phase 2 portion of the ongoing Phase 2/3 clinical trial of EB05 in critically ill COVID-19 patients. Last month, the independent Data and Safety Monitoring

Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions
19 Oct, 2021 FinancialContent

Edesa Biotech Inc(NASDAQ: EDSA) has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as ...

Edesa Biotech Is Now Above Resistance: Can It Continue Higher?
19 Oct, 2021 FinancialContent

Edesa Biotech Inc. (NASDAQ: EDSA) shares are trading higher Tuesday after the company announced additional results from the Phase 2 part ...

Why Edesa Biotech Shares Are Trading Higher Today
19 Oct, 2021 FinancialContent

Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday afterthe company announced additional results from the Phase 2 part of ...

Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study
19 Oct, 2021 FinancialContent
As Edesa Biotech, Inc. (NASDAQ:EDSA) gains 11%, insiders who bought last year may be wishing they had bet higher
09 Oct, 2021 Yahoo! Finance

Edesa Biotech, Inc. ( NASDAQ:EDSA ) insiders who bought shares over the past year were rewarded handsomely last week...

50 Biggest Movers From Yesterday
22 Sep, 2021 FinancialContent

Check out these big penny stock gainers and losersLosers Edesa Biotech, Inc. (NASDAQ: EDSA) shares dipped 29.9% to ...

Mid-Afternoon Market Update: Dow Edges Lower; Helbiz Shares Spike Higher
21 Sep, 2021 FinancialContent

Toward the end of trading Tuesday, the Dow traded down 0.11% to 33,932.34 while the NASDAQ rose 0.18% to 14,740.41. The S&P also ...

Mid-Day Market Update: Gold Rises 1%; Verrica Pharmaceuticals Shares Slide
21 Sep, 2021 FinancialContent

Midway through trading Tuesday, the Dow traded up 0.44% to 34,119.86 while the NASDAQ rose 0.66% to 14,810.89. The S&P also rose, ...

32 Stocks Moving In Tuesday's Mid-Day Session
21 Sep, 2021 FinancialContent

Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 177.4% to $39.83. Helbiz Media, the media arm of Helbiz announced a deal with ...

Mid-Morning Market Update: Markets Gain; AutoZone Earnings Beat Views
21 Sep, 2021 FinancialContent

Following the market opening Tuesday, the Dow traded up 0.14% to 34,017.77 while the NASDAQ rose 0.39% to 14,771.47. The S&P also ...

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
21 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Another busy day of trading is already underway as we look at the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

18 Stocks Moving in Tuesday's Pre-Market Session
21 Sep, 2021 FinancialContent

Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 37% to $1.78 in pre-market trading after declining around 4% on Monday. ReWalk ...

48 Biggest Movers From Yesterday
21 Sep, 2021 FinancialContent

Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 ...

EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday
20 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, the announcement of positive clinical trial results has sent investors in Edesa Biotech and EDSA stock on a nice ride. The post EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Why Edesa Biotech Shares Are Soaring Today
20 Sep, 2021 FinancialContent

Edesa Biotech Inc (NASDAQ: EDSA) is surginghigher Monday after the company announced positive Phase 2data of its monoclonal ...

Mid-Afternoon Market Update: Dow Tumbles 2.5%; BeyondSpring Shares Plunge
20 Sep, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded down 2.57% to 33,696.98 while the NASDAQ fell 3.14% to 14,572.25. The S&P also ...

How To Play Edsa Biotech's Stock After 60% Surge
20 Sep, 2021 FinancialContent

Edsa Biotech Inc. (NASDAQ: EDSA) shares are trading higher after the company announced Phase 2 Data of its Monoclonal Antibody in ...

Edesa Biotech Stock Is Rallying After COVID-19 Antibody Data: What You Need To Know
20 Sep, 2021 FinancialContent

Edesa Biotech Inc(NASDAQ: EDSA) hasannounced positive resultsfrom the Phase 2 part of an ongoing Phase 2/3 study ...

Mid-Day Market Update: Crude Oil Down 2%; Synlogic Shares Spike Higher
20 Sep, 2021 FinancialContent

Midway through trading Monday, the Dow traded down 1.51% to 34,063.71 while the NASDAQ fell 2.13% to 14,723.20. The S&P also fell, ...

35 Stocks Moving In Monday's Mid-Day Session
20 Sep, 2021 FinancialContent

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. ...

EDSA: EB05 Reduces Risk of COVID Death by 68.5% in Critically Ill Patients…
20 Sep, 2021 Yahoo! Finance

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Positive Results for Phase 2 Study of EB05 in Critically Ill COVID-19 Patients On September 20, 2021, Edesa Biotech, Inc. (NASDAQ:EDSA) announced positive results from the Phase 2 portion of the ongoing Phase 2/3 clinical trial of EB05 in critically ill COVID-19 patients. A total of approximately 360 patients, age

Mid-Morning Market Update: Markets Open Lower; Brooks Automation Divests Semiconductor Business For $3B
20 Sep, 2021 FinancialContent

Following the market opening Monday, the Dow traded down 1.42% to 34,093.46 while the NASDAQ fell 1.86% to 14,763.93. The S&P also ...

Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
20 Sep, 2021 FinancialContent
Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference
09 Sep, 2021 FinancialContent
EDSA: Awaiting End of Phase 2 Analysis of Phase 2/3 Study of EB05 in COVID19…
01 Sep, 2021 Yahoo! Finance

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Nearing End of Phase 2 Analysis for EB05 Phase 2/3 Trial in COVID-19 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a Phase 2/3 clinical trial of EB05 in patients hospitalized with COVID-19 with or at risk of developing acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The trial is

Edesa Biotech Provides Update For COVID-19 Antibody Trial
26 Aug, 2021 FinancialContent

Edesa Biotech Inc(NASDAQ: EDSA)issued an updatefor the Phase 2/3 study evaluating its monoclonal antibody ...

Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule
26 Aug, 2021 FinancialContent
Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results
13 Aug, 2021 FinancialContent

Edesa Biotech, Inc (EDSA) is a NASDAQ Common Stock listed in , ,

970x250